They were right on the money with a $.01 loss. That's what the Yahoo page has said all along. I see an article saying that it was a $.01 miss. In biotech, it really wouldn't matter much if it was off $.05 in either direction. You just have to be aware that people are crazy enough to trade that number as if it DID have meaning.
Nice reminder that the $83M that they raised netted $83M on 10.9M shares, which is a net of $7.61 a share and as a stockholder, you don't have to worry about them needing more cash and diluting the stock anytime in the near future, if ever again.
The Phase III endometiosis trial "screening subjects ..within the next few weeks". So, we won't have to wait until the end of the quarter to get more news on this.
VMAT II "This data is now sufficient to support the planned long-term Phase II trial that we have been talking about."
There is a yellow flag on Abbott maybe not having a signed SPA on the Phase III yet. The SPA is an agreement signed by the FDA stating that they agree that the clinical trial design is such that it should provide proper support or proper evidence of the drugs efficacy. I'm an administrator not a clinician, but I think my explanation is in the right ballpark. Anyway, why don't they have that yet? I am certain that it will be cleaned up, but you won't see this hitting nine bucks a share until they do. Also, we should get that update in two weeks!